Expression of e-cadherin in high-risk breast cancer
- First Online:
- 105 Downloads
E-cadherin expression is diverse, and differences in patient characteristics may produce variability in expression. Whereas some studies have indicated that downregulation of e-cadherin, associated with loss of cellular adhesiveness, was correlative with poor prognosis and metastasis, other studies have failed to confirm this. The present study uses a highly homogenous population of patients at high-risk for breast cancer, on the basis of ethnic and socio-economic status, to examine the relationship between e-cadherin and other prognostic markers in breast cancer.
Immunohistochemical staining was undertaken for estrogen (ER) and progesterone (PR) receptors, epidermal growth factor receptor 2 (Her-2), p53, vascular endothelial factor (VEGF), and hypoxia inducible factor 1α (HIF-1α) and the levels of these markers was compared to e-cadherin expression in a high-risk African-American patient population.
E-cadherin expression persisted into the later stagers of the disease, and was strongly associated with Her-2 and HIF-1α expression, but not p53, ER/PR or VEGF.
In contrast to other studies on heterogeneous populations, e-cadherin is preserved in aggressive tumors in this high-risk population. The ethnic and socio-economic risk stratification needs to be accounted for in studies correlating markers and prognosis.
KeywordsAggressive breast carcinoma E-cadherin HER-2 p53 VEGF HIF-1α Immunohistochemistry
Human epidermal growth receptor 2
Vascular endothelial growth factor
Ductal carcinoma in situ
Hypoxia inducible factor 1α
- Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle RJ, Boecker W (1999) Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopath 34:25–34CrossRefGoogle Scholar
- Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Beest P, Goovaerts G, Dirix LY, Van Dam P, Fox SB, Harris AL, Van Maarck EA (2003) Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong e-cadherin expression. Br J Cancer 88:718–725CrossRefPubMedGoogle Scholar
- Kochhar R, Howard EM, Tadros TS, Birdsong GG, Lyles RH, Lau SK (2003) Correlation of p53, her2neu, vascular endothelial growth factor (VEGF) and e-cadherin expression in adenocarcinoma of breast. Proc AACR 6213Google Scholar
- Palacios J, Benito N, Pizarro A, Limeres MA, Suarez A, Cano A, Gamallo C (1997) Relationship between ERBB2 and e-cadherin expression in human breast cancer. Virchows Arch 427:259–263Google Scholar
- Rose DP, Royak-Schaler, R (2001) Tumor biology and prognosis in black breast cancer: a review. Cancer Det Prev 25:16–31Google Scholar
- Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMedGoogle Scholar